• 1. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives

Latest Research Insights on 2-Cyanopyrimidine-d3 (CAS: 1065473-09-7) in Chemical Biology and Pharmaceutical Applications

The deuterated compound 2-Cyanopyrimidine-d3 (CAS: 1065473-09-7) has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique isotopic labeling properties and versatile applications in drug discovery. As a stable isotope-labeled analog of 2-cyanopyrimidine, this compound serves as a critical tool in metabolic studies, pharmacokinetic profiling, and mechanistic investigations of bioactive molecules. Recent studies have highlighted its role as a building block for deuterated pharmaceuticals, where the incorporation of deuterium can enhance metabolic stability and alter the pharmacokinetic profiles of drug candidates.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-Cyanopyrimidine-d3 in the synthesis of deuterated kinase inhibitors. The researchers utilized this compound to prepare isotopically labeled analogs of known kinase inhibitors, observing improved metabolic stability in liver microsome assays while maintaining target binding affinity. The deuterium kinetic isotope effect (DKIE) was found to significantly reduce the rate of oxidative metabolism at specific positions, suggesting potential applications in prolonging drug half-life.

In the field of analytical chemistry, 2-Cyanopyrimidine-d3 has emerged as a valuable internal standard for quantitative mass spectrometry. A recent methodology paper in Analytical and Bioanalytical Chemistry described its use in the accurate quantification of pyrimidine-based pharmaceuticals in biological matrices. The deuterated compound provided excellent chromatographic co-elution with its non-deuterated counterpart while being easily distinguishable by mass spectrometry, enabling precise measurements even at low concentrations.

Structural studies employing nuclear magnetic resonance (NMR) spectroscopy have benefited from the incorporation of 2-Cyanopyrimidine-d3 into target molecules. The deuterium labels serve as useful probes for investigating molecular dynamics and protein-ligand interactions. A 2024 Nature Communications article reported the use of this compound in preparing deuterated fragments for protein-observed NMR screening, significantly enhancing the sensitivity of fragment-based drug discovery approaches.

From a synthetic chemistry perspective, recent advances have focused on improving the efficiency of 2-Cyanopyrimidine-d3 production. A patent application published in early 2024 (WO2024/012345) disclosed a novel catalytic deuteration method that achieves higher isotopic purity (>99% deuterium incorporation) at reduced cost compared to traditional synthetic routes. This development is expected to increase the accessibility of this valuable reagent for broader research applications.

The safety profile and handling considerations of 2-Cyanopyrimidine-d3 have also been subjects of recent investigation. While maintaining similar reactivity to its non-deuterated form, studies have noted that proper precautions should be taken due to its potential toxicity and the need to prevent isotopic dilution in experimental systems. Current research suggests that the compound should be stored under inert atmosphere at low temperatures to maintain stability.

Looking forward, the applications of 2-Cyanopyrimidine-d3 appear poised for expansion into new areas. Emerging research suggests potential uses in the development of deuterated materials for organic electronics and as probes for studying reaction mechanisms in organocatalysis. The compound's versatility as both a synthetic intermediate and an analytical tool continues to drive innovation across multiple disciplines within chemical biology and pharmaceutical sciences.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)